Full Press Release Details
IDEAYA Announces First Patient In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA R pembrolizumab in Patients with Endometrial Cancer.
IDYA
IDEAYA Announces First Patient In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA R pembrolizumab in Patients with Endometrial Cancer
Key Takeaway: IDEAYA Announces First Patient In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA R pembrolizumab in Patients with Endometrial Cancer
Price reaction · baseline $27.73 (2024-12-09 close) · hit after-hours · 2 other IDYA headline(s) in the window, move may be shared
day 0 close
+0.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma